Letters
of a blood sample, presumably by recombining different proportions of plasma and red cells, but he then added glucose to a level of 11 mmoIlL. He does not explain how this was done, but he seems to have assumed that the glucose would equilibrate between red cells and plasma. This may well be so, but if it remained mainly in the plasma, it would tend to counterbalance any haematocrit effect and might explain why he observed none.
The HemoCue differs in that the red cells are lysed. Therefore, glucose release should be more rapid and complete than in the YSI technique. In this respect it is similar to the APEC analyser (UK agents Vital Scientific Ltd, Sussex, UK) in which whole blood and plasma are claimed to give very similar results with no significant haematocrit effect.
The Analox GM glucose analyser can be used to measure glucose in plasma, in whole blood with intact red cells or in lysed whole blood. the manufacturers report that intact whole blood gives results 12 to 140/0 lower than plasma and lysed blood shows intermediate values.
It seems that methods using lysed whole blood give higher results than those using intact whole blood. While cellular constituents other than glucose may interfere in some methods, lysis may also release more glucose than the dilution methods are able to in the limited time before measurement takes place. Further work is therefore needed to resolve this issue.
In conclusion, the situation is much more complex than Dr Jones's comments suggest. It is further complicated by the absence of a suitable independent reference method for whole blood systems and by the way in which systems are adjusted to give results expressed as whole blood glucose even when plasma glucose is actually measured. 
K. WIENER
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Ann Clin Biochem 1993: 30 Use of free l3-hCG in Down's syndrome screening
We would like to comment on a number of points raised by Kevin Spencer and his colleagues in their recent paper on the use of free~-hCG in Down's syndrome screening.' 77% detection rate for Down's syndrome It was concluded in the abstract that freẽ -hCG was the marker of choice in Down's syndrome screening and that when used early in the second trimester of pregnancy (at 14-16 weeks) in combination with o-fetcprotein (AFP) and maternal age, it would allow the detection of 77% of cases of Down's syndrome. This 77% estimate is meaningless alone; the corresponding false-positive rate must be specified.
The cited 77% detection rate is based on a subset of the data; attention was focused on the half of cases of Down's syndrome presenting at 14-16 weeks' gestation ( Table 9 in Spencer et al.). 1 The results for the remaining half of the cases (at 17or more weeks' gestation) were reported as yielding a smaller detection rate of 54%, a difference that was interpreted by the authors as showing that the test performs better before 17 weeks than afterwards. The higher detection rate in the earlier period may have been associated with a higher false-positive rate-countering the apparent advantage. Again, the data cannot be interpreted properly without specifying the corresponding false-positive rates. The percentages are inconsistent with data shown in their Fig. 2 which show that the average levels of free~-hCG, and therefore the corresponding detection rates, are similar for the two gestational periods. From this figure, we have calculated that the percent age of cases equal to or greater than 2'0 MoM was 60% at 14-16 weeks of gestation, and 70% at 17 weeks or more, proportions that are directionally the opposite of those claimed in their Table 9 . It is possible that the authors' conclusion that screening performance is better in the early gestational period than in the later one is confounded by maternal age and therefore not attributable to free~-hCG. Women seen earlier may be somewhat older, on average, than those who were seen later and for this reason tend to have higher risk estimates, leading to both a higher detection rate and a higher false-positive rate than the overall group.
The performance of free (i-hCG and total hCG as screening tests There are various estimates of the screening performance of free {j and total hCG given in the paper, and it is not obvious which result to use. The most direct ones on these two markers considered alone can be derived from their Tables 2 and 3. Using free {j-hCG alone the observed detection rate was 45' 5070 for a 5· 2070 falsepositive rate and using total hCG alone the detection rate was 38· 9070 for a 4· 9070 falsepositive rate. This dataset therefore shows that free {j-hCG yielded about 6070 more detection than total hCG alone for approximately the same 5070 false-positive rate.
Their Tables 7 and 8 present data suggesting that with maternal age and AFP, free {j yields up to an extra 10070 detection over total hCG. However, there has been an error in computing detection rates for total hCG in their Table 8 (and probably also in their Table 7 . but without the raw data we cannot be sure). Using the parameters of the underlying distributions cited by Spencer et al. (see their Table 6 ) it can be calculated that the detection rate using total hCG should be about 57070 for a 5070 false-positive rate (not 50% as given) when applied to the age distribution of England and Wales. The correct calculation therefore indicates a 2-3% increase in detection rather than the 10% increase claimed.
Truncation limits
The precise estimates of the detection rates and false-positive rates obtained from the multivariate model will depend on the truncation limits within which the distribution of the marker adequately fits a Gaussian distribution. This is of particular importance for free {j-hCG since observed free ,B-hCG values deviate from a Gaussian distribution beyond about 3· 0 MoMs, even after log transformation. Therefore, the false-positive rate will be underestimated unless appropriate truncation limits are selected. For example, the parameters listed in their Table 6 predict from the Gaussian model that 5 . 2, 3 . 0 and 0·9070 of the unaffected population will have free {j levels at or above 2'6, 3· 0 and 4·0 MoM, respectively, smaller than the values of 6'5,4'4 and 1'5070, respectively, that were actually observed. Our Table 1 shows the estimated detection and false-positive rates published in the paper together with our own calculations (i) with and without truncation limits, and (ii) with and without the use of unconjugated oestriol (uE]). Our calculations use the parameters in Table 6 of their paper applied to the Table 6 ). The mean uE] level in Down's syndrome pregnancies is 0'69 MoM, and the highest correlation coefficient between uE] and any other analyte (AFP) is 0'37 (r=0·14). These two pieces of information alone indicate that the addition of uE] must, on average, improve performance and not make it worse. This is confirmed by the application of the cited parameters which shows that the addition of uE] adds an extra 7% detection for a 5% false-positive rate (see Table 1 ).
Other numerical points
There are a number of other points in the paper that require clarification or correction. The distributions in the tables are inconsistent with the curves in their Fig. 3 ; the last total hCG point in their Fig. 3 appears to be misplotted (compare with their Figure 3 and Tables 2-3 in their paper are inconsistent with the parameters in their Table 6 with respect to AFP and uE] (see Table 2 ) but compare well for free {j-hCG and total hCG. From knowledge of other work on AFP and uE], the estimates based on the parameters in their (070) limits (070) +AFP (070) limits (070) limits (070) 
